Very late recurrences of leukemia: Why does leukemia awake after many years of dormancy?

Leukemia Research

Volumn 35, Issue 2, 2011, Pages 139-144

  Norkin, Maxim ^a,b   Uberti, Joseph P ^a   Schiffer, Charles A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Late relapse; Leukemia; Leukemia stem cell; Tumor dormancy

Indexed keywords

ANTHRACYCLINE; BLEOMYCIN; BUSULFAN; CD19 ANTIGEN; CD34 ANTIGEN; CHLORMETHINE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DASATINIB; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; HLA DR ANTIGEN; IMATINIB; METHOTREXATE; NELARABINE; PREDNISONE; PROCARBAZINE; THYMOCYTE ANTIBODY; VINBLASTINE; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CHILD; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CHROMOSOME TRANSLOCATION 11; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DISEASE DURATION; DORMANCY; DOSE RESPONSE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GRAFT REJECTION; GRANULOCYTIC SARCOMA; HUMAN; HUMAN TISSUE; KARYOTYPE; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAINTENANCE THERAPY; MALE; MIXED CELLULARITY HODGKIN LYMPHOMA; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RECURRENT CANCER; SCHOOL CHILD; SHORT TANDEM REPEAT; TREATMENT DURATION; TUMOR BIOPSY; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; CHILD; FEMALE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RECURRENCE; STEM CELL TRANSPLANTATION;

EID: 78751703163     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.09.016     Document Type: Letter

References (42)

1. Demicheli R., Terenziani M., Valagussa P., Moliterni A., Zambetti M., Bonadonna G. Local recurrences following mastectomy: support for the concept of tumor dormancy. J Natl Cancer Inst 1994, 86:45-48.
2. Uhr J.W., Scheuermann R.H., Street N.E., Vitetta E.S. Cancer dormancy: opportunities for new therapeutic approaches. Nat Med 1997, 3:505-509.
3. Pui C.H., Simone J.V., Hancock M.L., Evans W.E., Williams D.L., Bowman W.P., et al. Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: long-term results of St Jude total therapy study X. Leukemia 1992, 6:150-157.
4. Nygaard R., Moe P.J., Brincker H., Clausen N., Nyman R., Perkkio M., et al. Late relapses after treatment for acute lymphoblastic leukemia in childhood: a population-based study from the Nordic countries. Med Pediatr Oncol 1989, 17:45-47.
5. Jankovic M., Fraschini D., Amici A., Arico M., Arrighini A., Basso G., et al. Outcome after cessation of therapy in childhood acute lymphoblastic leukaemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica (AIEOP). Eur J Cancer 1993, 29A:1839-1843.
6. Miniero R., Saracco P., Pastore G., Zurlo M.G., Terracini B., Rosso P., et al. Relapse after first cessation of therapy in childhood acute lymphoblastic leukemia: a 10-year follow-up study. Italian Association of Pediatric Hematology-Oncology (AIEOP). Med Pediatr Oncol 1995, 24:71-76.
7. Salloum E., Pico J.L., Herait P., Bayle C., Ghosn M., Moran A., et al. Very late recurrence of childhood acute lymphoblastic leukemia treated with chemoimmunotherapy: a report of three cases occurring 19, 11, and 9 years after discontinuation of chemotherapy. Med Pediatr Oncol 1989, 17:155-158.
8. Levasseur M., Maung Z.T., Jackson G.H., Kernahan J., Proctor S.J., Middleton P.G. Relapse of acute lymphoblastic leukaemia 14 years after presentation: use of molecular techniques to confirm true re-emergence. Br J Haematol 1994, 87:437-438.
9. Geetha N., Lali V.S., Nileena N., Nair M.K. Late recurrence of childhood acute lymphoblastic leukemia. Am J Clin Oncol 1999, 22:191-192.
10. Nakasone H., Kida M., Iki S., Usuki K. Lower leukocytes at initial diagnosis may predict poor outcome of very late relapse of acute lymphoblastic leukemia. Leuk Res 2008, 32:659-664.
11. Rizzari C., Valsecchi M.G., Arico M., Miniero R., Messina C., De Rossi G., et al. Outcome of very late relapse in children with acute lymphoblastic leukemia. Haematologica 2004, 89:427-434.
12. Vora A., Frost L., Goodeve A., Wilson G., Ireland R.M., Lilleyman J., et al. Late relapsing childhood lymphoblastic leukemia. Blood 1998, 92:2334-2337.
13. Brincker H., Christensen B.E. Long-term survival and late relapses in acute leukaemia in adults. Br J Haematol 1990, 74:156-160.
14. Knudson A.G. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001, 1:157-162.
15. Mori H., Colman S.M., Xiao Z., Ford A.M., Healy L.E., Donaldson C., et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci U S A 2002, 99:8242-8247.
16. Eckert C., Einsiedel H.G., Hartmann R., von Stackelberg A., Volpel S., Guggemos A., et al. Clonal stability of initial leukemia in a child with central nervous system relapse 7.4 years after bone marrow relapse of common acute lymphoblastic leukemic. Haematologica 2004, 89:ECR23.
17. Almog N. Molecular mechanisms underlying tumor dormancy. Cancer Lett 2010, 294(2):139-146.
18. Gimbrone M.A., Leapman S.B., Cotran R.S., Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972, 136:261-276.
19. Indraccolo S., Stievano L., Minuzzo S., Tosello V., Esposito G., Piovan E., et al. Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment. Proc Natl Acad Sci U S A 2006, 103:4216-4221.
20. Fialkow P.J., Thomas E.D., Bryant J.I., Neiman P.E. Leukaemic transformation of engrafted human marrow cells in vivo. Lancet 1971, 1:251-255.
21. Hertenstein B., Hambach L., Bacigalupo A., Schmitz N., McCann S., Slavin S., et al. Development of leukemia in donor cells after allogeneic stem cell transplantation-a survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2005, 90:969-975.
22. Cooley L.D., Sears D.A., Udden M.M., Harrison W.R., Baker K.R. Donor cell leukemia: report of a case occurring 11 years after allogeneic bone marrow transplantation and review of the literature. Am J Hematol 2000, 63:46-53.
23. Flynn C.M., Kaufman D.S. Donor cell leukemia: insight into cancer stem cells and the stem cell niche. Blood 2007, 109:2688-2692.
24. Ruiz-Arguelles G.J., Ruiz-Arguelles A., Garces-Eisele J. Donor cell leukemia: a critical review. Leuk Lymphoma 2007, 48:25-38.
25. Medeiros B.C., Minden M.D., Schuh A.C., Schimmer A.D., Yee K., Lipton J.H., et al. Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years). Leuk Lymphoma 2007, 48:65-71.
26. Verma D., Kantarjian H., Faderl S., O'Brien S., Pierce S., Vu K., et al. Late relapses in acute myeloid leukemia: analysis of characteristics and outcome. Leuk Lymphoma 2010, 51(5):735-736.
27. Bennett J.M., Andersen J.W., Cassileth P.A. Long term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group (ECOG) experience. Leuk Res 1991, 15:223-227.
28. Ustun C., Kalla A., Bollag R.J., Manaloo E., Kulharya A., Jillella A. Relapsed acute myelogenous leukemia occurring after 18 years with recurrent novel chromosomal abnormality t(18;22)(q23;q11.2). Cancer Genet Cytogenet 2007, 177:135-138.
29. Duell T., van Lint M.T., Ljungman P., Tichelli A., Socie G., Apperley J.F., et al. Health and functional status of long-term survivors of bone marrow transplantation. EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. European Group for Blood and Marrow Transplantation. Ann Intern Med 1997, 126:184-192.
30. Goldman JM, Majhail NS, Klein JP, WangZ, Sobocinski KA, Arora M, et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J. Clin Oncol:28:1888-95.
31. Sekhri A., Liu D., Rasul M., Ahmed N., Ahmed T., Seiter K. Very late relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation. Leuk Res 2009, 33:1291-1293.
32. Daley G.Q., Van Etten R.A., Baltimore D. Blast crisis in a murine model of chronic myelogenous leukemia. Proc Natl Acad Sci U S A 1991, 88:11335-11338.
33. Mahon F.-X., Rea D., Guilhot F., Huguet F., Nicolini F.E., Legros L., et al. Discontinuation of imatinib therapy after achieving a molecular response in chronic myeloid leukemia patients. ASH Annu Meet Abstr 2009, 114. 859-
34. Witherspoon R.P., Fisher L.D., Schoch G., Martin P., Sullivan K.M., Sanders J., et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 1989, 321:784-789.
35. Hasegawa W., Pond G.R., Rifkind J.T., Messner H.A., Lau A., Daly A.S., et al. Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation. Bone Marrow Transplant 2005, 35:51-55.
36. Raghavan M., Lillington D.M., Skoulakis S., Debernardi S., Chaplin T., Foot N.J., et al. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res 2005, 65:375-378.
37. Vago L., Perna S.K., Zanussi M., Mazzi B., Barlassina C., Stanghellini M.T., et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 2009, 361:478-488.
38. Barrett J., Blazar B.R. Genetic trickery-escape of leukemia from immune attack. N Engl J Med 2009, 361:524-525.
39. Fialkow P.J., Singer J.W., Raskind W.H., Adamson J.W., Jacobson R.J., Bernstein I.D., et al. Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. N Engl J Med 1987, 317:468-473.
40. Fearon E.R., Burke P.J., Schiffer C.A., Zehnbauer B.A., Vogelstein B. Differentiation of leukemia cells to polymorphonuclear leukocytes in patients with acute nonlymphocytic leukemia. N Engl J Med 1986, 315:15-24.
41. Molldrem J.J., Lee P.P., Wang C., Felio K., Kantarjian H.M., Champlin R.E., et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000, 6:1018-1023.
42. Molldrem J.J., Lee P.P., Kant S., Wieder E., Jiang W., Lu S., et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest 2003, 111:639-647.